In the News

Find articles and press on AgeneBio and research updates regarding hippocampal overactivity and aMCI.

March 11, 2015

Trial Shows Current Drug Slows Alzheimer’s Onset

Science & Enterprise

A clinical trial testing a current drug to treat epilepsy shows the drug can delay development of Alzheimer’s disease in its earliest stages. Results of the study, conducted by researchers at Johns Hopkins University for AgeneBio Inc., two year-old pharmaceutical…

January 28, 2015

Phase 3 Trial of Epilepsy Drug for Cognitive Impairment To Be Initiated

Monthly Prescribing Reference

The Alzheimer’s Drug Discovery Foundation has awarded a $900,000 grant to AgeneBio to support the initiation of a Phase 3 clinical trial for AGB101. AGB101 is an investigational therapeutic treatment foramnestic mild cognitive impairment (aMCI).

March 26, 2014

AgeneBio Received US Patent

BioWorld Today

Agenebio Inc. was issued U.S. Patent No. 8,604,075, “Methods and compositions for improving cognitive function,” and No. 8,510,055, “Methods for characterizing and treating cognitive impairment in aging and disease.” Both cover the company’s programs for Alzheimer’s disease and other cognitive…

August 15, 2012

Brain Overactivity May Drive Disease Progress in Alzheimer’s

The Dana Foundation, Jim Schnabel

Evidence that brain overactivity occurs in early or pre-symptomatic Alzheimer’s has been building for over a decade. A UCLA brain-imaging study in 2000, for example, noted that middle aged and elderly people with the high-Alzheimer’s-risk apoE4 gene showed abnormally high…